May 7, 2020 / 5:19 AM / a month ago

BRIEF-Molecular Partners Q1 Operating Loss Of CHF 12.2 Mln

May 7 (Reuters) - MOLECULAR PARTNERS AG:

* CONTINUED PROGRESS ON ABICIPAR, SHARPENED FOCUS ON PIPELINE ACTIVITIES

* Q1 OPERATING LOSS OF CHF 12.2 MILLION AND NET LOSS OF CHF 13.3 MILLION

* IN 2020, MOLECULAR PARTNERS ANTICIPATES REGULATORY DECISIONS BY FDA AND EUROPEAN MEDICINES AGENCY (EMA) REGARDING MARKET LAUNCH OF ABICIPAR FOR PATIENTS WITH NAMD

* NO GUIDANCE CAN BE PROVIDED WITH REGARD TO NET CASH FLOW PROJECTIONS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below